Harmony Biosciences has named Adam Zaeske its chief commercial officer, luring the Takeda veteran back from Europe to lead a push to turn Wakix into a blockbuster and prepare to launch other drugs. More: Eyeing blockbuster sales, Harmony names Takeda
read moreInternational vaccine partnership Gavi has discontinued a COVID vaccine advance purchase agreement with Clover Biopharmaceuticals of China and is asking for repayment of $224 million. More: Gavi terminates COVID vaccine deal with Clover, demands 4M repayment Source: fierce
read moreTOMS Capital Investment Management picked up a stake at the consumer health drugmaker and is pushing for a full sale or separation of some assets, Bloomberg reported. More: After Starboard Value gets a seat on the board, another activist investor
read moreNovo Nordisk has quickly expanded its discounted Wegovy program, now offering all eligible cash-paying customers its popular weight-loss med at $499 per month. More: Novo Nordisk offers cheaper Wegovy for all cash-paying patients at retail pharmacy Source: fierce
read moreBiogen on Monday said it signed a 15-year lease for a building at Cambridge’s Kendall Common that the company plans to use as its new global headquarters. The Big Biotech says it will move its current Cambridge-based employees to the
read moreThe FDA has once again issued a complete response letter to Hengrui and Elevar’s applications for camrelizumab and rivoceranib in first-line liver cancer, with manufacturing again being the issue. More: FDA rejects Hengrui, Elevar's PD-1 cancer drug combination—again Source: fierce
read more© 1994 - 2026 B.M. Pharmaceuticals